Use the search bar to search by drug, manufacturer, or indication. You can also filter your search results by drug, manufacturer, or negotiation status.
To learn more about a specific file, click on a drug name. It will open its product card, which includes information about the manufacturer, indication (the approved use of a drug by Health Canada), and negotiation milestones.
There are 6 negotiation statuses, which reflect where the drug file is in the pCPA process:
Under consideration for negotiation
We’re considering the evidence and gathering other information to inform the negotiation approach, including eligibility for expedited negotiation pathways.
Active negotiation
Negotiation activities are underway for the drug, with our negotiation team and the manufacturer meeting regularly.
Concluded with an LOI
Negotiations ended successfully with mutually agreed-upon terms, and these terms are outlined in a letter of intent (LOI).
Concluded without agreement
Negotiating parties couldn’t agree on terms. Negotiations have ended without a pricing agreement for the drug.
Negotiation not pursued
It has been decided, in partnership with our member drug plans, not to engage in a negotiation. Typically, this is because the drug’s health technology (HTA) assessment reimbursement recommendations were negative, or “do not reimburse.” Other reasons, like the manufacturer declining to negotiate or a lack of supply of the drug in Canada, may be reflected in an accompanying status note.
Negotiation on hold
We began negotiation activities for the drug, but they’ve since been paused. An accompanying status note indicates whether the pause was requested by the manufacturer or the pCPA.
Learn more
To learn more about our negotiation processes, or where the pCPA fits into the Canadian drug reimbursement system, consult these pages:
Status:
Concluded with an LOI
Manufacturer:
EMD Serono Canada, a division of EMD Inc.
Indication:
Luveris, for the stimulation of follicular development in women, as part of an assisted procreation activity, administered concomitantly with follitropin
Last updated October 13, 2026
Ringza (segesterone acetate and ethinyl estradiol vaginal system)
Status:
Under consideration for negotiation
Manufacturer:
Duchesnay Inc.
Indication:
for use by women of reproductive potential to prevent pregnancy
Last updated October 13, 2026
Status:
Concluded with an LOI
Manufacturer:
EMD Serono Canada, a division of EMD Inc.
Indication:
For the stimulation of follicular development in women, as part of an assisted procreation activity, administered concomitantly with follitropin
Last updated October 13, 2026
Status:
Concluded with an LOI
Manufacturer:
Apotex Inc.
Indication:
In combination with cisplatin and gemcitabine, for the first-line treatment of adults with metastatic or with recurrent, locally advanced nasopharyngeal carcinoma (NPC).
Last updated October 13, 2026
Recarbrio (imipenem, cilastatin and relebactam)
Status:
Under consideration for negotiation
Manufacturer:
Merck Canada Inc.
Indication:
for the treatment of patients with the following infections caused by the designated susceptible Gram-negative microorganisms
Last updated October 7, 2026
Status:
Active negotiation
Manufacturer:
Medison Pharma Canada Inc.
Indication:
For the treatment of adult patients with indolent systemic mastocytosis (ISM) with moderate to severe symptoms inadequately controlled on symptomatic treatment.
Last updated October 7, 2026
Status:
Under consideration for negotiation
Manufacturer:
Horizon Therapeutics Canada
Indication:
as an add-on to standard therapy for the treatment of gMG in adult patients who are AChR or MuSK antibody positive
Last updated October 1, 2026
Status:
Under consideration for negotiation
Manufacturer:
Horizon Therapeutics Canada
Indication:
Adults with immunoglobulin G4-related disease
Last updated October 1, 2026
Status:
Under consideration for negotiation
Manufacturer:
KYE Pharmaceuticals Inc.
Indication:
For the treatment of Duchenne muscular dystrophy (DMD) in patients 4 years of age and older.
Last updated October 1, 2026
Lupron Depot (leuprolide acetate)
Status:
Active negotiation
Manufacturer:
AbbVie Corporation
Indication:
Advanced prostate cancer
Last updated September 25, 2026